Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Eikon Therapeutics, Inc. Common Stock (EIKN)
Millbrae, CA, US
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -9.45% | -14.88% | -10.59% | -31.35% | -29.07% | -29.07% | -29.07% | -29.07% | -29.07% | -29.07% | -29.07% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
5.00
-49.2%
|
| Last Quarter | 1 |
5.00
-49.2%
|
| Last Year | 1 |
5.00
-49.2%
|
| All Time | 1 |
5.00
-49.2%
|
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-12 | Wedbush | Underperform | Underperform | Maintain |
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ProShares - Nanotechnology ETF TINY | 0.82% | 390.4K | 0.58% |
| 2 | ALPS Medical Breakthroughs ETF SBIO | 0.29% | 625.5K | 0.50% |
| 3 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.15% | 414.9K | 0.39% |
| 4 | iShares Health Innovation Active ETF BMED | 0.12% | 13.3K | 0.77% |
| 5 | iShares Micro-Cap ETF IWC | 0.05% | 772.2K | 0.60% |
| 6 | iShares Russell 2000 Growth ETF IWO | 0.01% | 1.49M | 0.24% |
| 7 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 251.7K | 0.30% |
| 8 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.01% | 23.5K | 0.25% |
| 9 | Global X - Russell 2000 ETF RSSL | 0.01% | 107.2K | 0.08% |
| 10 | iShares Russell 2000 BuyWrite ETF IWMW | 0.01% | 3.8K | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Roger Perlmutter | Chairman, President & CEO | 842.2K | — |
| Roy D. Baynes FACP | Executive VP & Chief Medical Officer | 762.8K | — |
| Michael A. Klobuchar | Chief Operating Officer | 713.8K | male |
| Eric Betzig | Co-Founder & Member of Scientific Advisory Board | — | male |
| Robert Tjian | Co-Founder & Member of Scientific Advisory Board | — | — |
| Alfred Lloyd Bowie Jr. | Treasurer & CFO | — | — |
| Russ Berman | Chief Technology Officer | — | male |
| Barbara Howes | Chief People Officer | — | female |
| Benjamin Thorner | Secretary, General Counsel & Chief Business Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EIKN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
